CN116784480A - Composition containing hydrolyzed collagen II and application thereof - Google Patents
Composition containing hydrolyzed collagen II and application thereof Download PDFInfo
- Publication number
- CN116784480A CN116784480A CN202310667319.9A CN202310667319A CN116784480A CN 116784480 A CN116784480 A CN 116784480A CN 202310667319 A CN202310667319 A CN 202310667319A CN 116784480 A CN116784480 A CN 116784480A
- Authority
- CN
- China
- Prior art keywords
- parts
- product
- composition
- group
- hydrolyzed collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 108010035532 Collagen Proteins 0.000 title claims abstract description 30
- 102000008186 Collagen Human genes 0.000 title claims abstract description 30
- 229920001436 collagen Polymers 0.000 title claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 241000287828 Gallus gallus Species 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 21
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 21
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 18
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 241000208829 Sambucus Species 0.000 claims abstract description 16
- 235000018735 Sambucus canadensis Nutrition 0.000 claims abstract description 16
- 235000007123 blue elder Nutrition 0.000 claims abstract description 16
- 235000007124 elderberry Nutrition 0.000 claims abstract description 16
- 235000008995 european elder Nutrition 0.000 claims abstract description 16
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 13
- 239000005913 Maltodextrin Substances 0.000 claims description 12
- 229920002774 Maltodextrin Polymers 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229940035034 maltodextrin Drugs 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229920002148 Gellan gum Polymers 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 239000000216 gellan gum Substances 0.000 claims description 8
- 235000010492 gellan gum Nutrition 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 8
- 235000011164 potassium chloride Nutrition 0.000 claims description 8
- 235000010241 potassium sorbate Nutrition 0.000 claims description 8
- 239000004302 potassium sorbate Substances 0.000 claims description 8
- 229940069338 potassium sorbate Drugs 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 210000001188 articular cartilage Anatomy 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 235000008935 nutritious Nutrition 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 9
- 210000002966 serum Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000001503 joint Anatomy 0.000 description 9
- 201000008482 osteoarthritis Diseases 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000000503 Collagen Type II Human genes 0.000 description 7
- 108010041390 Collagen Type II Proteins 0.000 description 7
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 6
- 208000018937 joint inflammation Diseases 0.000 description 6
- 235000013995 raspberry juice Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000647 trehalose group Chemical group 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008414 cartilage metabolism Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014268 sports nutrition Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 208000034311 hand osteoarthritis Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition containing hydrolyzed collagen II and application thereof, wherein the composition comprises the following components in parts by weight: 0.5 to 10 parts of hydrolyzed collagen II, 5 to 100 parts of trehalose, 0.1 to 10 parts of chicken protein peptide and 0.1 to 5 parts of elderberry juice powder. The preparation method of the composition containing hydrolyzed collagen II is simple, and can effectively protect the bone joint and improve the inflammation of the bone joint.
Description
Technical Field
The invention belongs to the field of sports nutrition food, and particularly relates to a composition for improving osteoarticular inflammation function and application thereof.
Background
Sports food generally refers to food specially processed to meet the physiological metabolic state, exercise capacity and special requirements for certain nutritional ingredients of the sports crowd, and can pointedly supplement nutritional substances lost in the exercise process, so as to improve the exercise capacity. In long-distance running, the body of people mainly uses fat and carbohydrate functions, and the fat stores more energy, but has lower energy efficiency, and once the exercise intensity exceeds 60-70% of the maximum oxygen uptake, the energy brought by decomposing fat is insufficient to maintain the body function. In general, the body has a limited content of carbohydrates stored in muscle and blood in the form of glycogen, and most human bodies can maintain a movement amount of about 2 hours during long-running, and most marathon runners cannot complete a race before glycogen is consumed, thus requiring energy to be supplemented during exercise.
In addition, long-term exercise causes injury to the joint of the human bone or joint inflammation, and factors causing joint inflammation include: abnormal cartilage metabolism: after the cells at the basal part of the cartilage are stimulated by the outside, the metabolic activity is enhanced, so that the regulation mechanism is disordered, and osteoarthritis can be caused. Enzyme action: joint inflammation is often accompanied by synovial inflammation, which can cause rise of intra-articular pressure, so that acid phosphatase and other secretion are increased, and cartilage is damaged; change of chemical composition: the proportion of water in the cartilage is gradually reduced, so that the cartilage is gradually changed, the cartilage is denatured for a long time, the joint wear is increased, and the joint inflammation is caused; human nutrition changes: insufficient nutrition can lead to reduced intra-articular fluid volume, and cell proliferation is affected, so that cartilage injury is not easy to repair and gradually changes into arthritis. Sports injuries, more commonly athletes such as football players, ankle osteoarthritis, knee osteoarthritis, etc., and also hand osteoarthritis of pianists, are also caused by overuse. Osteoarthritis tends to occur earlier in long-term sports people such as athletes or in people who overuse joints for a long period of time, which is the result of overuse of joints.
Currently, there is a lack of product sports foods for the protection of osteoarthritis and bone joints in the market, especially energy glues for the protection of bone joints during energy supplementation.
Disclosure of Invention
In view of the above problems in the prior art, according to one aspect of the present invention, one of the technical problems to be solved by the present invention is to provide a composition, which comprises the following components in parts by weight: 0.5 to 10 parts of hydrolyzed collagen II, 5 to 100 parts of trehalose, 0.1 to 10 parts of chicken protein peptide and 0.1 to 5 parts of elderberry juice powder.
Preferably, the composition comprises the following components in parts by weight: 0.5 to 5 parts of hydrolyzed collagen II, 10 to 50 parts of trehalose, 0.1 to 5 parts of chicken protein peptide and 0.1 to 3 parts of elderberry juice powder.
Preferably, the composition comprises the following components in parts by weight: 1 part of hydrolyzed collagen II, 10 parts of trehalose, 0.225 part of chicken protein peptide and 0.7 part of elderberry juice powder.
Preferably, the composition further comprises an auxiliary material, wherein the auxiliary material is one or more selected from the group consisting of highly branched cyclodextrin, maltodextrin, vitamin C, edible salt, potassium chloride, sodium citrate, xanthan gum, gellan gum, citric acid, sucralose, potassium sorbate and essence for food.
Preferably, in the composition, the auxiliary materials comprise the following components in parts by weight: 10-200 parts of highly branched cyclodextrin, 10-200 parts of maltodextrin, 20-50 parts of sucralose, 10-200 parts of maltodextrin, 0.01-100 parts of vitamin C, 50-100 parts of sodium citrate, 20-50 parts of xanthan gum, 100-150 parts of gellan gum, 20-30 parts of sea salt, 100-150 parts of potassium chloride, 5-15 parts of potassium sorbate or 30-120 parts of edible essence.
Another technical problem solved by the present invention is to provide the use of the above composition in any one of (a 1) preparing a product for ameliorating osteoarticular inflammation; (a 2) preparing a product for improving articular cartilage; (a 3) preparing a product for protecting bone joints.
Preferably, the product is a health product, a pharmaceutical product or a sports nutritional food.
Preferably, the sports nutritional food is selected from the group consisting of energy bars, energy gums, powders.
A further technical problem addressed by the present invention is to provide a product comprising a composition as described above, said product having any one of the following uses, (b 1) for ameliorating osteoarthritis; (b 2) for improving articular cartilage; (b 3) a product for protecting bone joints.
The composition for improving osteoarticular inflammatory function according to the present invention is used in an amount of: 10-28 g/day.
According to one aspect of the invention, the third technical problem to be solved by the invention is to provide the application of the composition with the function of improving osteoarticular inflammation in preparing sports nutrition food.
Preferably, the sports nutritional food is selected from: energy stick, energy glue, powder.
The invention has the beneficial effects that:
the composition with the function of improving osteoarticular inflammation has a simple preparation method, and can effectively protect osteoarticular and improve osteoarticular inflammation.
Detailed Description
Hereinafter, preferred embodiments of the present disclosure will be described in detail. Before the description, it should be understood that the terms used in the specification and the appended claims should not be construed as limited to general and dictionary meanings, but interpreted based on the meanings and concepts corresponding to technical aspects of the present invention on the basis of the principle that the inventor is allowed to define terms appropriately for the best explanation. Accordingly, the description herein is for the purpose of illustrating preferred examples only and is not intended to limit the scope of the invention, as it will be understood that other equivalent implementations and modifications may be made without departing from the spirit and scope of the invention.
The following examples are merely illustrative of embodiments of the present invention and are not intended to limit the invention in any way, and those skilled in the art will appreciate that modifications may be made without departing from the spirit and scope of the invention. Unless otherwise specified, reagents and equipment used in the following examples are commercially available products.
All features or conditions defined herein in terms of numerical ranges or percentage ranges are for brevity and convenience only. Accordingly, the description of a numerical range or percentage range should be considered to cover and specifically disclose all possible sub-ranges and individual values within the range, particularly integer values. For example, a range description of "1 to 8" should be taken as having specifically disclosed all sub-ranges such as 1 to 7, 2 to 8, 2 to 6, 3 to 6, 4 to 8, 3 to 8, etc., particularly sub-ranges defined by all integer values, and should be taken as having specifically disclosed individual values such as 1, 2, 3, 4, 5, 6, 7, 8, etc. within the range. The foregoing explanation applies to all matters of the invention throughout its entirety unless indicated otherwise, whether or not the scope is broad.
If an amount or other numerical value or parameter is expressed as a range, preferred range, or a series of upper and lower limits, then it is understood that any range, whether or not separately disclosed, from any pair of the upper or preferred value for that range and the lower or preferred value for that range is specifically disclosed herein. Furthermore, where a range of numerical values is recited herein, unless otherwise stated, the range is intended to include the endpoints thereof, and all integers and fractions within the range.
In this context, numerical values should be understood to have the accuracy of the numerical significance of the numerical values provided that the objectives of the present invention are achieved. For example, the number 40.0 is understood to cover a range from 39.50 to 40.49.
In the composition having the function of improving osteoarticular inflammation according to the present invention:
hydrolysis of collagen type II: treating rheumatoid arthritis and osteoarthritis by alleviating pain, stiffness and discomfort symptoms, and improving patient mobility.
Trehalose: the anti-chondrocyte apoptosis effect is achieved by increasing the activity of the organism antioxidant enzyme and reducing the release of inflammatory factors.
Chicken protein peptide: pain in patients with knee arthritis is reduced by antioxidant effect and immune function modulation;
bone raspberry juice powder: can remove oxygen free radical, relieve organism inflammation, and prevent and treat osteoporosis.
EXAMPLE 1 composition containing hydrolyzed collagen II
The embodiment provides a composition containing hydrolyzed collagen II, which comprises the following components in parts by mass: 1 part of hydrolyzed collagen II, 10 parts of trehalose, 0.225 part of chicken protein peptide and 0.7 part of elderberry juice powder.
The preparation method of the composition containing hydrolyzed collagen II in the embodiment comprises the following steps: taking the raw materials of the hydrolyzed collagen II, the trehalose, the chicken protein peptide and the elderberry juice powder according to the proportion, and fully mixing the raw materials to obtain a mixture.
Example 2 composition containing hydrolyzed collagen II
The embodiment provides a composition containing hydrolyzed collagen II, which comprises the following components in parts by mass: 1.5 parts of hydrolyzed collagen II, 15 parts of trehalose, 2.25 parts of chicken protein peptide and 0.85 part of elderberry juice powder.
The preparation method of the composition containing hydrolyzed collagen II in the embodiment comprises the following steps: taking the raw materials of the hydrolyzed collagen II, the trehalose, the chicken protein peptide and the elderberry juice powder according to the proportion, and fully mixing the raw materials to obtain a mixture.
Example 3 composition containing hydrolyzed collagen II
The embodiment provides a composition containing hydrolyzed collagen II, which comprises the following components in parts by mass: 2 parts of hydrolyzed collagen II, 20 parts of trehalose, 4 parts of chicken protein peptide and 1 part of elderberry juice powder.
The preparation method of the composition containing hydrolyzed collagen II in the embodiment comprises the following steps: taking the raw materials of the hydrolyzed collagen II, the trehalose, the chicken protein peptide and the elderberry juice powder according to the proportion, and fully mixing the raw materials to obtain a mixture.
Example 4 preparation of energy gel for protecting Joint and improving osteoarticular inflammation
The preparation process of the energy glue for protecting joints and improving osteoarticular inflammation of the embodiment comprises the following steps:
step one, taking the composition in the example 1;
step two, taking the following auxiliary materials in parts by weight: 30 parts of sucralose, 450 parts of maltodextrin, 60 parts of vitamin C, 60 parts of sodium citrate, 40 parts of xanthan gum, 125 parts of gellan gum, 25 parts of sea salt, 125 parts of potassium chloride, 10 parts of potassium sorbate, 75 parts of edible essence and 2000 parts of pure water.
Thirdly, manually premixing xanthan gum, gellan gum, sucralose, potassium sorbate and chicken protein peptide powder which are main components in the first step and the second step, and hydrolyzing II-type collagen to be A material in advance for 1-10min.
Adding pure water into the emulsifying tank at normal temperature, adding maltodextrin in the second step under stirring, adding the material A after the maltodextrin is fully dissolved, heating to 90 ℃, preserving heat for 10min, dissolving sodium citrate, potassium chloride, edible salt (sea salt) and vitamin C in water of about 50-75 ℃ in advance, adding the emulsifying tank, continuously stirring for 5-15min, and detecting the solid content; cooling the feed liquid to below 70deg.C, adjusting acid with citric acid aqueous solution, and flavoring to obtain the final product.
Example 5 preparation of energy gel for protecting Joint and improving osteoarticular inflammation
The preparation process of the energy glue for protecting joints and improving osteoarticular inflammation of the embodiment comprises the following steps:
step one, taking the composition in the example 2;
step two, taking the following auxiliary materials in parts by weight: 30 parts of sucralose, 450 parts of maltodextrin, 60 parts of vitamin C, 60 parts of sodium citrate, 40 parts of xanthan gum, 125 parts of gellan gum, 25 parts of sea salt, 125 parts of potassium chloride, 10 parts of potassium sorbate, 75 parts of edible essence and 2200 parts of pure water.
Thirdly, manually premixing xanthan gum, gellan gum, sucralose, potassium sorbate and chicken protein peptide powder which are main components in the first step and the second step, and hydrolyzing II-type collagen to be A material in advance for 1-10min.
Adding pure water into the emulsifying tank at normal temperature, adding maltodextrin in the second step under stirring, adding the material A after the maltodextrin is fully dissolved, heating to 90 ℃, preserving heat for 10min, dissolving sodium citrate, potassium chloride, edible salt (sea salt) and vitamin C in water of about 50-75 ℃ in advance, adding the emulsifying tank, continuously stirring for 5-15min, and detecting the solid content; cooling the feed liquid to below 70deg.C, and adjusting acid with citric acid aqueous solution to obtain the final product.
Test example: the composition of the invention is used for protecting bone joints and improving bone joint inflammation test 1.1 study objects:
35 male university students of Beijing sports university with exercise habits are selected as study objects. The study subjects all met the following criteria: 1. knee joint injury caused by sports, types of sports including track and field (such as running, marathon, hiking, climbing), ball (such as badminton, tennis, basketball, football), fight (such as taekwondo, martial arts, boxing, wrestling, judo, etc.); 2. no history of severe knee joint trauma fracture; koos scale total score <60 score.
In addition, subjects meeting the following criteria were excluded: 1. knee joint surgery was accepted for the past 3 months; 2. taking non-steroidal anti-inflammatory drugs during the last 3 months, taking supplements containing glucosamine, chondroitin sulfate, curcumin, collagen, trehalose + chicken protein peptide + bone raspberry juice powder 3. Injecting hyaluronic acid during the first 2 weeks or corticosteroid during 3 months; 4. treatment with joint medications is required during the study.
The recruiter was subjected to a general case test and KOOS questionnaire test in the form of a web questionnaire distribution before the start of the experiment, and the recruited subjects met inclusion criteria and were subjected to an exclusion procedure. Subjects after inclusion signed informed consent prior to the experiment. The subjects were randomly divided into a group of collagen type ii (group a, group ii, trehalose), a group of chicken protein peptides (group B, group C, group chicken protein peptides), a group of elderberry juice powder (group D, group bone raspberry juice powder), a group of example 1 (group E, group ii, composition of trehalose, chicken protein peptides, bone raspberry juice powder), a group of example 2 (group F, group ii, composition of trehalose, chicken protein peptides, bone raspberry juice powder, group 2), a group of example 3 (group G, group ii, composition of trehalose, chicken protein peptides, bone raspberry juice powder, group 2).
Table 1 subject base condition statistics
1.2 dietary control and nutritional supplements
During the experiment, all subjects were asked to eat the same food at the same place and at the same time, and for 1 day 3 meals, caloric intake was calculated as 45 kcal per kg body weight per day, with caloric ratios of three major energy substances of 65% carbohydrate, 15% protein, 20% fat. The experimental diet is started one week before the experiment starts, and no drinking, caffeine intake, night cooking and other actions occur.
Nutritional products were taken daily after the start of the experiment, group a: type ii collagen administration, group B: trehalose administration, group C: chicken protein peptide administration, group D: the composition of example 1 of the present invention was administered as the elderberry juice powder, as the E group, as the F group, as the composition of example 2 of the present invention, as the G group, as the composition of example 3 of the present invention. The nutritional products are taken once a day, 40g each time, and are brewed with warm water.
1.3 study methods:
1.3.1 Experimental design
The study on whether the composition of the II type collagen, trehalose, chicken protein peptide and elderberry juice powder can improve the damage of articular cartilage after 90 days is supplemented.
No vigorous exercise was performed three days before the start of the test, and a fasting of 22:00 was initiated the day before the start of the test. The next eight am arrives at the test site, the KOOS questionnaire is filled out, venous blood is then withdrawn, and a 30 day dose of the supplement is dispensed on site for the corresponding subject group. Thereafter, on day 90, the KOOS questionnaire was filled in again at the same site and venous blood was then withdrawn. The remaining supplement is provided to the subject on site for 30 days, 60 days, as received or mailed.
1.3.2 test index
1. Knee joint injury and osteoarthritis outcome score (KOOS)
2. Blood index examination: 1) Inflammation index: CRP, TNF-alpha; 2) Cartilage metabolism index: serum type II collagen C-terminal peptide (CTX-II, type II collagen degradation product), serum cartilage oligomeric matrix protein (COMP, cartilage matrix destruction degradation released into blood), serum type II procollagen N-terminal propeptide (PIINP, synthetic type II collagen procollagen).
1.4 statistical analysis
All measured data are expressed as mean ± standard deviation (x±sd) and are counted and analyzed using SPS25.0 software. Each index between and within the group was analyzed by one-way variance analysis, with P <0.05 indicating significant level differences.
2 experimental results
2.1 Effect of 90 day combination item intervention on total score of subject KOOS questionnaire
As shown in table 2, there was an increase in the total KOOS questionnaire score for the 4 groups of subjects after 90 days of experimental intervention. E. F, G group of subjects had significantly higher increases in KOOS questionnaire total score than group a, group B, group C, group D (P < 0.05), and F, G significantly higher than group E. Each group of interventions was suggested to improve the symptoms of joint inflammation and the compositions of examples 2, 3 of the present invention were more effective.
Table 2: effect of 90 day intervention on KOOS questionnaire score
Note that: aP <0.05, indicating that the same index differs statistically from group a;
b P<0.05, which indicates that the same index has statistical significance as compared with the group B;
c P<0.05, which indicates that the same index has statistical significance as compared with the group C;
d P<0.05, which indicates that the same index has statistical significance as compared with the difference of the group D;
e P<0.05, which indicates that the same index is statistically different from group E.
2.2 Effects of 90-day combination intervention on serum CRP, TNF-alpha in subjects
As shown in table 3, 90-day experimental intervention reduced the serum CRP, TNF- α levels in the subjects. E. The subjects in group F, G had significantly higher serum CRP, TNF- α levels than in groups a, B, C, D (P < 0.05), and F, G significantly higher than in group E, and G significantly higher than in group F. Each set of interventions was suggested to improve joint inflammatory factor release and the composition of example 3 of the present invention works better.
Table 3: effects of 90-day intervention on serum CRP, TNF- α
Note that: a P<0.05, which indicates that the same index has statistical significance as compared with the group A;
b P<0.05, indicating that the same index has statistical significance as compared to group BMeaning;
c P<0.05, which indicates that the same index has statistical significance as compared with the group C;
d P<0.05, which indicates that the same index has statistical significance as compared with the difference of the group D;
e P<0.05, which indicates that the same index has statistical significance as compared with the group E;
f P<0.05, which indicates that the same index is statistically different from group F.
2.3 Effects of 90 day combination intervention on subject serum CTX-II, COMP, PIINP
As shown in table 4, 90-day experimental intervention reduced serum CTX-II and COMP levels in the subject. E. The subjects in group F, G had significantly higher serum CTX-II, COMP levels than in groups a, B, C, D (P < 0.05), and F, G significantly higher than in group E. Each set of interventions was suggested to improve the breakdown of articular cartilage and the compositions of examples 2, 3 of the present invention were more effective.
Table 4: effects of 90-day intervention on serum CTX-II, COMP
Note that: a P<0.05, which indicates that the same index has statistical significance as compared with the group A;
b P<0.05, which indicates that the same index has statistical significance as compared with the group B;
c P<0.05, which indicates that the same index has statistical significance as compared with the group C;
d P<0.05, which indicates that the same index has statistical significance as compared with the difference of the group D;
e P<0.05, which indicates that the same index has statistical significance as compared with the group E;
f P<0.05, which indicates that the same index is statistically different from group F.
In addition, as shown in table 5, 90-day experimental intervention increased serum PIINP levels in subjects. The rise in serum PIINP levels was significantly higher in all subjects in group E than in groups a, B, C, D (P < 0.05). Each set of interventions was suggested to increase the level of synthesis of articular cartilage and the composition of example 2 of the present invention works better.
Table 5: effect of 90-day experimental intervention on serum PIINP
Note that: a P<0.05, which indicates that the same index has statistical significance as compared with the group A;
b P<0.05, which indicates that the same index has statistical significance as compared with the group B;
c P<0.05, which indicates that the same index has statistical significance as compared with the group C;
d P<0.05, which indicates that the same index has statistical significance as compared with the difference of the group D;
e P<0.05, which indicates that the same index has statistical significance as compared with the group E;
f P<0.05, which indicates that the same index is statistically different from group F.
The experimental data of the experimental examples prove that the composition provided by the invention has good effects of protecting the bone joint and improving the osteoarticular inflammation.
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (10)
1. The composition comprises the following components in parts by weight: 0.5 to 10 parts of hydrolyzed collagen II, 5 to 100 parts of trehalose, 0.1 to 10 parts of chicken protein peptide and 0.1 to 5 parts of elderberry juice powder.
2. The composition according to claim 1, wherein the composition comprises the following components in parts by weight: 0.5 to 5 parts of hydrolyzed collagen II, 10 to 50 parts of trehalose, 0.1 to 5 parts of chicken protein peptide and 0.1 to 3 parts of elderberry juice powder.
3. The composition according to claim 1, wherein the composition comprises the following components in parts by weight: 1 part of hydrolyzed collagen II, 10 parts of trehalose, 0.225 part of chicken protein peptide and 0.7 part of elderberry juice powder.
4. A composition according to any one of claims 1 to 3, further comprising an auxiliary material selected from one or more of highly branched cyclodextrin, maltodextrin, vitamin C, table salt, potassium chloride, sodium citrate, xanthan gum, gellan gum, citric acid, sucralose, potassium sorbate and food flavors.
5. The composition of claim 4, wherein,
in the composition, the auxiliary materials comprise the following components in parts by weight: 10-200 parts of highly branched cyclodextrin, 10-200 parts of maltodextrin, 20-50 parts of sucralose, 10-200 parts of maltodextrin, 0.01-100 parts of vitamin C, 50-100 parts of sodium citrate, 20-50 parts of xanthan gum, 100-150 parts of gellan gum, 20-30 parts of sea salt, 100-150 parts of potassium chloride, 5-15 parts of potassium sorbate or 30-120 parts of edible essence.
6. The composition according to any one of claims 1-5 for use in any one of (a 1) preparing a product for ameliorating osteoarticular inflammation;
(a2) Preparing a product for improving articular cartilage;
(a3) And preparing a product for protecting the bone joint.
7. The use according to claim 6, wherein,
the product is health product, medicine or sports nutritious food.
8. The use according to claim 7, wherein,
the sports nutritious food is selected from energy bar, energy gel and powder.
9. A product comprising the composition of any one of claims 1 to 3, said product having any one of the uses,
(b1) For improving osteoarticular inflammation;
(b2) For improving articular cartilage;
(b3) A product for protecting bone joints.
10. The product according to claim 9, wherein,
the dosage of the product is 10-28 g/day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310667319.9A CN116784480A (en) | 2023-06-07 | 2023-06-07 | Composition containing hydrolyzed collagen II and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310667319.9A CN116784480A (en) | 2023-06-07 | 2023-06-07 | Composition containing hydrolyzed collagen II and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116784480A true CN116784480A (en) | 2023-09-22 |
Family
ID=88047365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310667319.9A Pending CN116784480A (en) | 2023-06-07 | 2023-06-07 | Composition containing hydrolyzed collagen II and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116784480A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970064621A (en) * | 1997-07-29 | 1997-10-13 | 김재홍 | A therapeutic agent for collagen-induced arthritis containing peptides of type II collagen as an active ingredient |
| US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| WO2008014685A1 (en) * | 2006-07-24 | 2008-02-07 | Peixue Ling | Formulation containing trehalose for intraarticular injection |
| CN108112997A (en) * | 2017-12-18 | 2018-06-05 | 北京康比特体育科技股份有限公司 | A kind of health-care food composition |
| CN109567157A (en) * | 2018-10-23 | 2019-04-05 | 北京同仁堂健康药业股份有限公司 | A kind of composition and preparation method thereof for improving bony articulation health |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| CN113261671A (en) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | Bovine bone peptide composition for preventing and improving osteoporosis and application thereof |
| CN114085285A (en) * | 2021-12-08 | 2022-02-25 | 美泰科技（青岛）股份有限公司 | Preparation method and application of high-purity II type collagen peptide with bone joint maintenance effect |
| CN114557448A (en) * | 2022-03-28 | 2022-05-31 | 江西蝌蚪科技有限公司 | Preparation easy to be absorbed by human body and capable of improving human cartilage tissue and preparation method |
| CN115669931A (en) * | 2021-07-29 | 2023-02-03 | 以岭健康科技有限公司 | Sports nutrition powder containing elderberry and capable of relieving sports fatigue and preparation method of sports nutrition powder |
-
2023
- 2023-06-07 CN CN202310667319.9A patent/CN116784480A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970064621A (en) * | 1997-07-29 | 1997-10-13 | 김재홍 | A therapeutic agent for collagen-induced arthritis containing peptides of type II collagen as an active ingredient |
| US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| WO2008014685A1 (en) * | 2006-07-24 | 2008-02-07 | Peixue Ling | Formulation containing trehalose for intraarticular injection |
| CN108112997A (en) * | 2017-12-18 | 2018-06-05 | 北京康比特体育科技股份有限公司 | A kind of health-care food composition |
| CN109567157A (en) * | 2018-10-23 | 2019-04-05 | 北京同仁堂健康药业股份有限公司 | A kind of composition and preparation method thereof for improving bony articulation health |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| CN113261671A (en) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | Bovine bone peptide composition for preventing and improving osteoporosis and application thereof |
| CN115669931A (en) * | 2021-07-29 | 2023-02-03 | 以岭健康科技有限公司 | Sports nutrition powder containing elderberry and capable of relieving sports fatigue and preparation method of sports nutrition powder |
| CN114085285A (en) * | 2021-12-08 | 2022-02-25 | 美泰科技（青岛）股份有限公司 | Preparation method and application of high-purity II type collagen peptide with bone joint maintenance effect |
| CN114557448A (en) * | 2022-03-28 | 2022-05-31 | 江西蝌蚪科技有限公司 | Preparation easy to be absorbed by human body and capable of improving human cartilage tissue and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| SJGLE食品加工包装在线: "鸡肉蛋白肽有利于提高有氧代谢，增强代谢过程", pages 1 - 2, Retrieved from the Internet <URL:https://m.sjgle.com/article/article_id/49526.html> * |
| 施百利: "受欢迎的接骨木莓有什么神奇之处？", pages 1, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s/1HE5H-XD62mV2fibRD4VRg> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5840715A (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
| CN101317684B (en) | Solid beverage and preparation method there of | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN109152749A (en) | For treating or preventing the impaired alimentation composition of mobility | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN102178934B (en) | Preparation for increasing bone mineral density, preventing osteoarthrosis and enhancing immunity | |
| CN104126808A (en) | Weight-reducing health-care food and preparation method thereof | |
| CN111467481A (en) | Composition for improving and/or preventing osteoarthritis and application thereof | |
| KR20070113460A (en) | The health food composition for regulating weight | |
| KR20200016608A (en) | The health food composition for regulating weight | |
| CN116784480A (en) | Composition containing hydrolyzed collagen II and application thereof | |
| CN110638055A (en) | Collagen peptide composite sheet | |
| CN104223120A (en) | Food formula containing low-molecule chondroitin sulfate for special diet for patients suffering from meniscus injury | |
| WO2019011911A1 (en) | Medicament and beverage for improving joint and bone diseases | |
| JP2015013845A (en) | Low back pain preventing and/or improving agent, and food and drink for low back pain prevention | |
| CN103238839A (en) | Food composition containing collagen used for maintaining joints | |
| JP4143387B2 (en) | healthy food | |
| CN111655250A (en) | Composition for preventing or improving nociceptive pain | |
| CN110664994A (en) | Composition for treating osteoarticular diseases | |
| CN108066363A (en) | A kind of nourishing the liver body building composition | |
| EP3714890B1 (en) | Composition comprising a collagen hydrolysate and a fucoidan | |
| CN114159553A (en) | Composition comprising collagen hydrolysate and fucoidan | |
| JP2011223965A (en) | Foodstuff compound containing collagen | |
| US20220080031A1 (en) | Composition comprising a collagen hydrolysate and a fucoidan | |
| Świąder et al. | Dietary Supplements Containing Collagen–Analysis and Availability on the Polish Market® |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |